Deutsch English Français

Contact

EP2421850

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP2421850

EP2421850 - 3 -AZABICYCLO [4.1.0]HEPTANES USED AS OREXIN ANTAGONISTS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 05.07.2013 Database last updated on 09.07.2024
Most recent event Tooltip	05.07.2013	Application deemed to be withdrawn	published on 07.08.2013 [2013/32]
Applicant(s)	For all designated states Glaxo Group Limited Glaxo Wellcome House Berkeley Avenue Greenford Middlesex UB6 0NN / GB
	[2012/09]
Inventor(s)	01 / AMANTINI, David GlaxoSmithKline SpA Via Alessandro Fleming 2 I-37135 Verona / IT
	02 / FERRONI, Francesco GlaxoSmithKline SpA Via Alessandro Fleming 2 I-37135 Verona / IT
	03 / GIANOTTI, Massimo GlaxoSmithKline SpA Via Alessandro Fleming 2 I-37135 Verona / IT
	04 / PAVONE, Francesca GlaxoSmithKline SpA Via Alessandro Fleming 2 I-37135 Verona / IT
	05 / DI FABIO, Romano c/o GlaxoSmithKline SpA Via Alessandro Fleming 2 37135 Verona / IT
	[2012/09]
Former [N/P]	01 / AMANTINI, David GlaxoSmithKline SpA Via Alessandro Fleming 2 I-37135 Verona / IT
	02 / FERRONI, Francesco GlaxoSmithKline SpA Via Alessandro Fleming 2 I-37135 Verona / IT
Representative(s)	Lawrence, Geoffrey Mark Prouse GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB
	[N/P]
Former [2012/09]	Lawrence, Geoffrey Mark Prouse GlaxoSmithKline Corporate Intellectual Property (CN925.1) 980 Great West Road Brentford Middlesex TW8 9GS / GB
Application number, filing date	10715239.9	23.04.2010
	WO2010EP55449
Priority number, date	GB20090007112	24.04.2009 Original published format: GB 0907112
	GB20090010483	17.06.2009 Original published format: GB 0910483
	GB20090022472	22.12.2009 Original published format: GB 0922472
	[2012/09]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2010122151
	Date:	28.10.2010
	Language:	EN
	[2010/43]
	Type:	A1 Application with search report
	No.:	EP2421850
	Date:	29.02.2012
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 28.10.2010 takes the place of the publication of the European patent application.
	[2012/09]
Search report(s)	International search report - published on:	EP	28.10.2010
Classification	IPC:	C07D401/12, C07D403/14, C07D413/14, C07D417/14, A61K31/44, A61K31/501, A61K31/506, A61P3/04, A61P25/22, A61P25/24, A61P25/30	[2012/09]
	CPC:	C07D401/12 (EP,KR,US); A61K31/444 (KR); A61P11/00 (EP); A61P25/00 (EP); A61P25/20 (EP); A61P25/22 (EP); (+) A61P25/24 (EP); A61P25/30 (EP); A61P3/04 (EP); A61P43/00 (EP); A61P9/00 (EP); C07D401/14 (KR); C07D403/14 (EP,US); C07D413/14 (EP,US); C07D417/14 (EP,US) (-)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2012/09]
Extension states	AL	21.10.2011
	BA	21.10.2011
	ME	21.10.2011
	RS	21.10.2011
Title	German:	ALS OREXINANTAGONISTEN VERWENDETE 3-AZABICYCLO[4.1.0]HEPTANE	[2012/09]
	English:	3 -AZABICYCLO [4.1.0]HEPTANES USED AS OREXIN ANTAGONISTS	[2012/09]
	French:	3 -AZABICYCLO [4.1.0]HEPTANES UTILISÉS COMME ANTAGONISTES DE L'OREXINE	[2012/09]
Entry into regional phase	21.10.2011	National basic fee paid
	21.10.2011	Designation fee(s) paid
	21.10.2011	Examination fee paid
Examination procedure	21.10.2011	Amendment by applicant (claims and/or description)
	21.10.2011	Examination requested [2012/09]
	14.09.2012	Despatch of a communication from the examining division (Time limit: M04)
	25.01.2013	Application deemed to be withdrawn, date of legal effect [2013/32]
	04.03.2013	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2013/32]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 14.09.2012
Fees paid	Renewal fee
	21.03.2012	Renewal fee patent year 03
	Penalty fee
	Additional fee for renewal fee
	30.04.2013	04 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[AD]WO02089800 (SMITHKLINE BEECHAM PLC [GB], et al) [AD] 1-23 * claims 1,10; table 2 *;
		[A]WO03051368 (SMITHKLINE BEECHAM PLC [GB], et al) [A] 1-23 * claims 1,7 *;
		[AD]WO2008038251 (ACTELION PHARMACEUTICALS LTD [CH], et al) [AD] 1-23* page 1, line 1 - line 5; claim 1 *
	by applicant	WO9201810
		WO9634877
		EP0849361
		EP0875565
		EP0875566
		EP0893498
		WO9909024
		WO9958533
		WO0047577
		WO0047580
		WO0047576
		WO0196302
		WO0244172
		WO02089800
		WO03002559
		WO03002561
		WO03032991
		WO03037847
		WO03041711
		WO2005118548
		WO2008038251
		WO2009003993
		WO2009003997
		- SAKURAI, T. ET AL., CELL, (1998), vol. 92, pages 573 - 585
		- SMART ET AL., BRITISH JOURNAL OF PHARMACOLOGY, (1999), vol. 128, pages 1 - 3
		- WILLIE ET AL., ANN. REV. NEUROSCIENCES, (2001), vol. 24, pages 429 - 458
		- SAKURAI, NATURE REVIEWS NEUROSCIENCE, (2007), vol. 8, pages 171 - 181
		- OHNO; SAKURAI, FRONT. NEUROENDOCRINOLOGY, (2008), vol. 29, pages 70 - 87
		- PEYRON ET AL., J. NEUROSCIENCES, (1998), vol. 18, pages 9996 - 10015
		- WHITE ET AL., PEPTIDES, (2005), vol. 26, pages 2231 - 2238
		- HAGAN ET AL., PROC.NATL.ACAD.SCI., (1999), vol. 96, pages 10911 - 10916
		- CHEMELLI ET AL., CELL, (1999), vol. 98, pages 437 - 451
		- LEE ET AL., J. NEUROSCIENCE, (2005), vol. 25, pages 6716 - 6720
		- PIPER ET AL., EUROPEAN J NEUROSCIENCE, (2000), vol. 12, pages 726 - 730
		- SMART; JERMAN, PHARMACOLOGY AND THERAPEUTICS, (2002), vol. 94, pages 51 - 61
		- SMITH ET AL., NEUROSCIENCE LETTERS, (2003), vol. 341, pages 256 - 258
		- BRISBARE-ROCH ET AL., NATURE MEDICINE, (2007), vol. 13, no. 2, pages 150 - 155
		- BORGLAND ET AL., NEURON, (2006), vol. 49, no. 4, pages 589 - 601
		- BOUTREL ET AL., PROC.NATL.ACAD.SCI., (2005), vol. 102, no. 52, pages 19168 - 19173
		- HARRIS ET AL., NATURE, (2005), vol. 437, pages 556 - 559
		- BERGE; BIGHLEY; MONKHOUSE, J.PHARM.SCI, (1977), vol. 66, pages 1 - 19
		- LAMBERT DG, Calcium Signaling Protocols, HUMANA PRESS, (1999), pages 125 - 136
		- BOWEN WP; JERMAN JC., "Nonlinear regression using spreadsheets", TRENDS PHARMACOL SCI., (1995), vol. 16, doi:doi:10.1016/S0165-6147(00)89091-4, pages 413 - 417, XP004207565 DOI: http://dx.doi.org/10.1016/S0165-6147(00)89091-4
		- BIOCHEM. PHARMACOL., (1973), vol. 22, pages 3099 - 3108

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p